Systemic Lupus Erythematosus

You have full text access to this OnlineOpen article

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia

  1. Myles J. Lewis,
  2. Talat H. Malik,
  3. Liliane Fossati-Jimack,
  4. Daniele Carassiti,
  5. H. Terence Cook,
  6. Dorian O. Haskard,
  7. Marina Botto*

Article first published online: 27 JUL 2012

DOI: 10.1002/art.34451

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 64, Issue 8, pages 2707–2718, August 2012

Additional Information

How to Cite

Lewis, M. J., Malik, T. H., Fossati-Jimack, L., Carassiti, D., Cook, H. T., Haskard, D. O. and Botto, M. (2012), Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis & Rheumatism, 64: 2707–2718. doi: 10.1002/art.34451

Author Information

  1. Imperial College London, London, UK

*Centre for Complement and Inflammation Research, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK

Publication History

  1. Issue published online: 27 JUL 2012
  2. Article first published online: 27 JUL 2012
  3. Accepted manuscript online: 5 MAR 2012 03:42PM EST
  4. Manuscript Accepted: 21 FEB 2012
  5. Manuscript Received: 2 AUG 2011

Funded by

  • Wellcome Trust. Grant Number: program grant 088517
  • Wellcome Trust Clinical Research Fellowship
  • British Heart Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1136K)

REFERENCES

  • 1
    Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–15.
  • 2
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406.
  • 3
    Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–15.
  • 4
    Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato K, et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004; 199: 1121–31.
  • 5
    Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2006; 103: 7018–23.
  • 6
    Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, et al. ApoE−/−Fas−/− C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res 2007; 48: 794–805.
  • 7
    Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F, Gremy G, et al. Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler Thromb Vasc Biol 2007; 27: 1625–31.
  • 8
    Ma Z, Choudhury A, Kang SA, Monestier M, Cohen PL, Eisenberg RA. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008; 127: 168–75.
  • 9
    Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56–9.
  • 10
    Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 2007; 170: 416–26.
  • 11
    Ait-Oufella H, Pouresmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R, et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1429–31.
  • 12
    Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe−/− mice. Arterioscler Thromb Vasc Biol 2008; 28: 1421–8.
  • 13
    Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 2007; 115: 2168–77.
  • 14
    Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004; 304: 1147–50.
  • 15
    Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002; 196: 135–40.
  • 16
    Carlucci F, Cortes-Hernandez J, Fossati-Jimack L, Bygrave AE, Walport MJ, Vyse TJ, et al. Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 loci when expressed on C57BL/6 mice. J Immunol 2007; 178: 2352–60.
  • 17
    Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 417–26.
  • 18
    Malik TH, Cortini A, Carassiti D, Boyle JJ, Haskard DO, Botto M. The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2010; 122: 1948–56.
  • 19
    Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717–25.
  • 20
    Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002; 323: 3–10.
  • 21
    Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994; 93: 1885–93.
  • 22
    Carlucci F, Fossati-Jimack L, Dumitriu IE, Heidari Y, Walport MJ, Szajna M, et al. Identification and characterization of a lupus suppressor 129 locus on chromosome 3. J Immunol 2010; 184: 6256–65.
  • 23
    Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1569–76.
  • 24
    Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800–14.
  • 25
    Verdeguer F, Castro C, Kubicek M, Pla D, Vila-Caballer M, Vinue A, et al. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. Cardiovasc Res 2007; 76: 340–50.
  • 26
    Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–7.
    Direct Link:
  • 27
    Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol 2008; 19: 478–82.
  • 28
    Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335: 1643–9.
  • 29
    Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci U S A 2001; 98: 1787–92.
  • 30
    Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007; 46: 983–8.
  • 31
    Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025–31.
  • 32
    Matthijsen RA, de Winther MP, Kuipers D, van der Made I, Weber C, Herias MV, et al. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 119: 2188–95.
  • 33
    Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192: 359–66.
  • 34
    Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004; 173: 6366–75.
  • 35
    Yumura W, Hattori S, Morrow WJ, Mayes DC, Levy JA, Shirai T. Dietary fat and immune function. II. Effects on immune complex nephritis in (NZB × NZW)F1 mice. J Immunol 1985; 135: 3864–8.
  • 36
    Levy JA, Ibrahim AB, Shirai T, Ohta K, Nagasawa R, Yoshida H, et al. Dietary fat affects immune response, production of antiviral factors, and immune complex disease in NZB/NZW mice. Proc Natl Acad Sci U S A 1982; 79: 1974–8.
  • 37
    Lin BF, Huang CH, Chiang BL, Jeng SJ. Dietary fat influences Ia antigen expression, cytokines and prostaglandin E2 production of immune cells in autoimmune-prone NZB × NZW F1 mice. Br J Nutr 1996; 75: 711–22.
  • 38
    Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369–78.
  • 39
    Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959–71.
  • 40
    Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731–40.
  • 41
    Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110: 2552–8.
  • 42
    Schiopu A, Bengtsson J, Soderberg I, Janciauskiene S, Lindgren S, Ares MP, et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110: 2047–52.
  • 43
    Tisseverasinghe A, Lim S, Greenwood C, Urowitz M, Gladman D, Fortin PR. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2211–9.
    Direct Link:
View Full Article (HTML) Get PDF (1136K)